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Summary DNA Ploidy and S phase fraction (SPF) were measured in Stage I and II breast cancers from
patients with at least 8 years of follow-up, to assess the prognostic significance of these data. Disaggregated
sections of formalin-fixed, paraffin-embedded tumour were analysed by flow cytometry. SPF was calculated
using a rectangular model of S phase, after subtraction of background debris using an exponential model.
64% of tumours were DNA aneuploid. The median SPF was 4.5% for DNA diploid, and 10.9% for DNA
aneuploid tumours. There were small reductions in survival at 10 years for DNA aneuploid tumours, and for
tumours with above median SPF, but these were not statistically significant. The relative hazard for DNA
aneuploid tumours was 1.20 (95% CI 0.81-1.76), and for high SPF was 1.31 (95% CI 0.87-1.98). Neither
factor was statistically correlated with survival in multivariate analysis. Technical and theoretical factors limit
the accuracy and reproducibility of flow cytometric data, and may explain the lack of prognostic information
given.
Since the publication of a technique for using paraffin
embedded tissue for flow cytometry (Hedley et al., 1983),
there have been many reports of the prognostic significance
of DNA ploidy and S phase fraction (SPF) in breast cancer.
Seven large series (>300 patients) with long follow up () 5
years median) have used multivariate analysis to assess the
independence of observed effects, but with variable results
(Cornelisse et al., 1987; Hedley et al., 1987; Kallionemi et al.,
1988; Clark et al., 1989; Toikkanen et al., 1989; Stal et al.,
1989; Fisher et al., 1991). We have studied these variables in
a large cohort of homogeneously treated patients with breast
cancer who have been followed up for a median period of
over 10 years, paying particular attention to technical factors
which may be responsible for the varying results obtained by
previous workers, and report here upon this experience.
Patients and methods
Patients
Patients included in this study were part of the Liverpool
Breast Cancer Series, recruited between 1978 and 1982. All
were treated in the first instance by total mastectomy with
axillary dissection alone, with no adjuvant therapy. Treat-
ment of subsequent recurrence was open, and chemotherapy
and/or endocrine therapy were given to a number of patients
within the study. A total of 749 patients were entered into
this series. Paraffin-embedded blocks of tumour were sought
for all of these patients and were found for a total of 329
cases. This group forms the basis of the current report. The
large number of cases in which no block was available was in
large part due to the closure of two of the four hospitals in
which the operations had originally been performed. This
was not felt to introduce a selection bias into the cohort
available for study.
Patients have been prospectively followed up and flagged
in the Regional Cancer Registry. They were treated in four
hospitals in the Merseyside region, two of which have since
closed. For this reason, data on recurrence is incomplete, and
analysis has only been performed in respect of survival data.
The close of the study was taken as the 1st of January 1990,
at which time the minimum follow up of surviving patients
was 93 months.
Methods
DNA measurement
Ssections of 4 and 50 yt were cut from one block of primary
tumour from each patient. The thin section was H & E
stained to verify the presence of a majority of tumour tissue.
Thick sections were processed by the technique of Hedley et
al. (1983). Sections were wrapped in 501t nylon mesh and
taken through xylene and graded alcohols to water on a
tissue processor. The rehydrated tissue was then transferred
to plastic tubes and incubated with 0.5% pepsin in 0.9%
saline, adjusted to pH 1.5 for 30 min at 37°C, in order to free
nuclei. The suspension was washed twice with PBS and then
stained with propridium iodide at 30 1tg ml-' in the presence
of 100 tg ml-' RNAase and 0.25% Triton X-100 for 30min
at room temperature. Following this the stained nuclei were
resuspended in PBS. Specimens were then analysed on a
Coulter Epics Profile II flow cytometer with a 15 mW argon
laser emitting at 488 nm, counting 10,000 events at a rate of
approximately 00 s'-. Red fluorescence was collected using
550 nm long pass dichroic mirror and 610 nm band pass
filter. The ploidy histogram was gated on a two dimensional
peak versus integral signal histogram in order to eliminate
doublets.
Assessment ofploidy
Ploidy histograms were reviewed by a panel of four, and
classified as DNA diploid or DNA aneuploid by consensus.
In cases of doubt, repeat sections were processed and the two
histograms reviewed together. Internal standards were not
added to nuclei for flow cytometry, due to the known varia-
tion in DNA staining exhibited by paraffin embedded
material (Hedley et al., 1985). All presumptively DNA
aneuploid histograms showed a substantial population of
DNA diploid cells, which acts as an internal standard. His-
tograms were classified as DNA aneuploid if more than one
discrete population was identified. The DNA index was then
assigned as the ratio between the mean channel number for
the aneuploid GO/GI peak, and the mean channel for the
GO/GI peak of the normal cell population within the histog-
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ram. Diploid tumours have a DNA index of 1.0. Polyploid
tumours (those with two or more aneuploid populations of
different DNA content) were not assigned a DNA index.
Two objective criteria were employed in histogram interp-
retation.:
(a) histograms were regarded as uninterpretable for ploidy if
the half-peak coefficient of variation for the DNA diploid
GO/GI peak was > 10. Repeat specimens of these blocks
were run;
(b) the range of normal for the ratio between G2/M and the
corresponding GO/GI peaks was taken to be 1.85-2.10. Dis-
tinct peaks of any size outside this range were regarded as
DNA aneuploid if there was a detectable corresponding G2/
M peak. Peaks within this range were regarded as represen-
ting tetraploid populations if they accounted for > 15% of
the total histogram events, but only in the presence of a
recognisable G2/M peak.
Calculation ofSPF
SPF was estimated for each histogram by a single operator
using the Cytologics offline analysis software package
(Coulter Electronics). Histograms were regarded as interp-
retable for SPF if the half peak CV of the DNA diploid
GO/GI peak was <8%. In the case of DNA aneuploid
tumours it was also necessary that some part of the DNA
aneuploid population S phase was clearly separate from the
usually overlying DNA diploid G2/M peak. Exponential
background subtraction was carried out using operator-
defined regions either side of the true populations within the
histogram. Full peaks were then operator defined, to avoid
the inaccuracy of computer identification with its assumption
of Gaussian peak shape. The SPF was then calculated using
a rectangular model of S phase.
For the purposes of analysis, SPF in DNA diploid and
DNA aneuploid tumours have been treated separately. In an
DNA aneuploid histogram the specific population under
study is separate in the histogram from the DNA diploid
population attributable to normal breast cells, non-DNA
aneuploid tumour clones, tumour lymphocytes and connec-
tive tissue cells. In a DNA diploid histogram these two
populations are superimposed, with a consequent 'dilution'
of the study population. The SPF as measured in an DNA
aneuploid histogram is that of the DNA aneuploid clone
alone, whereas the SPF measured in a DNA diploid histog-
ram is that of the total population of cells in the tumour. If
we accept that the SPF of non-tumour elements may well be
different from that of the tumour, then the two cannot be
assumed to be analogous, although many previous reports
have assumed that they are.
Other data
Nodal status and tumour size were determined by the hos-
pital pathologist reporting each case. ER assays were per-
formed using the dextran coated charcoal technique, with a
cut off of 5 fmol oestradiol mg cytosol protein '. neu staining
was performed with the 21N polyclonal antibody (a gift of
Dr W. Gullick). Tumours were regarded as positive if any
areas of tumour membrane staining were seen.
Statistical methods
Survival analyses were carried out to relate survival to
ploidy, SPF, lymph node status (positive or negative),
tumour size (TI, T2, T3), oestrogen receptor status (positive
or negative), and neu staining (positive or negative). Patients
known to be alive at Jan 1st, 1990 or who were known to
have died from causes unrelated to cancer, were treated as
censored observations. Univariate analysis was performed
using Kaplan-Meier estimates and log rank tests. In light of
the differences between SPF as calculated in DNA diploid
and DNA aneuploid tumours, the effect of this variable was
analysed separately for the two ploidy groups. A combined
analysis using a common median was also done, on the
grounds that this was the method used in other reports.
Multivariate analyses used the Cox proportional hazards
regression model, using both forward and backward selection
of variables. The tests sought interactions within a model
containing the effects of six prognostic variables - ER status,
node status, size, neu status, ploidy and SPF. SPF was
analysed as a binary variable, above or below the median
appropriate to the ploidy of that particular tumour.
Results
Patient characteristics
Histological review indicated that 36 of the blocks examined
showed no remaining tumour. The distribution of prognostic
factors within the remaining group of 293 patients is
indicated in Table I.
Ploidy
Histograms meeting the criteria enunciated in the methods
section were obtained in 281 cases (96% of those with
tumour-containing blocks). One hundred and seventy-nine
(64%) of these were DNA aneuploid, and 102 were DNA
diploid. The median CV for the GO/GI peak in these 281
histograms was 5.6% (interquartile range 4.6-7.0%). The
distribution of DNA indices is shown in Figure 1. Univariate
analysis of survival stratified by ploidy is shown in Figure 2.
There is a survival advantage in favour of DNA diploid
tumours of 4% at 5 years and of 3% at 10 years, but this
result is not statistically significant. Expressed in terms of a
hazards ratio, the relative hazard for patients with DNA
aneuploid tumours is 1.20 with 95% confidence limits of
0.81-1.76.
SPF
Estimates of SPF were obtained in 226 cases (80% of those
from which ploidy was interpretable). The median value of
Table I Characteristics of the study population
Variable Subgroups %
Nodal status No 57
Ni 43
Tumour size TI 9
T2 71
T3 20
ER status Pos 59
Neg 41
neu status Pos 23
Neg 77
Menopausal status Pre 38
Post 62
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Figure 1 Frequency histogram showing distribution of DNA
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Figure 2 Life table of disease-related mortality for DNA aneup-
loid and DNA diploid tumours (log rank chi-square = 1.19, 1 df,
P = 0.28).
SPF was 7.25% overall, 4.5% in DNA diploid tumours and
10.9% in DNA aneuploids. No attempt has been made to
compare the distributions of values for DNA diploid and
DNA aneuploid tumours statistically, because of the different
nature of the measurement in the two types of histogram.
Life tables for survival for these populations split at the
respective medians are shown in Figure 3. Neither of these
analyses show a statistically significant survival effect os SPF.
Analysis was also performed within each ploidy group using
quartiles of SPF, to assess whether there was an effect
restricted to extreme values, but there was no evidence that
this was the case. The relative hazard for all tumours with
above median SPF, regardless of ploidy, is 1.31 with 95%
confidence intervals 0.87-1.98 (Figure 4).
114 98 73 61 27 Number
112 87 66 55 25 at risk
Figure 4 Life table of disease-related mortality stratified by SPF
below and above the overall median of 7.25% (log rank chi-
square = 2.61, I df, P= 0.11).
those for which SPF was available. In a stepwise procedure
with all terms starting out of the model, only nodal status is
found to be independently prognostic (coefficient 0.67, stan-
dard error 0.22, relative hazard 1.96, 95% CI 1.27-3.01).
The same result is obtained with a model where all terms
start in.
The prognostic effect of ploidy was also analysed in all 255
cases where ploidy, ER status, nodal status, neu status and
size were available. Adjusting for these factors, no indepen-
dent prognostic effect for ploidy was observed (coefficient
0.22, standard error 0.20, relative hazard 1.24, 95% CI
0.83-1.87).
Discussion
Multivariate analysis
This was carried out in the 201 cases where all prognostic
variables were available for that tumour. This represents
72% of tumours for which ploidy was measured, and 89% of
a
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Figure 3 Life tables of disease-related mortality for a, DNA
aneuploid, and b, DNA diploid tumours stratified by SPF below
or above the median for that tumour type (log rank chi-
square = 3.40, 3 df, P = 0.33).
We have observed that neither tumour ploidy nor SPF are
statistically significant independent prognostic factors in this
series of breast cancers. The previous literature upon this
subject is confusing. Many reports based upon the flow
cytometric study of archival material have been carried out
since the technique was developed in 1985. They have been
comprehensively reviewed by Merkel and McGuire (1990)
and Frierson (1991). Some of these reports are based upon
only small numbers of patients, others have studied very
diverse groups ofpatients who have had a variety of different
primary treatments, many have used short periods of follow-
up for a disease characterised by significant late mortality,
and a number have failed to apply multivariate analysis to
their findings in order to control for the effect of known
prognostic factors within their study group.
Seven reports of which we are aware studied more than
300 patients, followed for a median of at least 5 years, and
analysed using multivariate techniques. Cornelisse et al.
(1987) studied 565 patients with all stages of disease, for up
to 10 years, and found DNA aneuploidy to be an indepen-
dent adverse prognostic factor. In a series of 472 tumours
with a minimum of 6 years offollow-up studied by StAl et al.
(1989), however, ploidy was not an independent prognostic
variable. Tumours with a low SPF showed improved survival
independent of tumour size, nodal status and ER content,
although this was not broken down by ploidy status. They
noted that the relationship between disease recurrence and
SPF was not significant over the entire follow-up period
while controlling for other variables, suggesting that the pro-
gnostic value of SPF was reduced by the multivariate
analysis.
Toikkanen et al. (1989) reported upon the very long term
follow-up of 351 patients in whom both ploidy and SPF were
measured. Although ploidy predicted strongly for survival at
25 years, this result was not borne out in multivariate
analysis. SPF did show independent prognostic significance
with low SPF predicting for survival, but SPF was entered as
above or below a figure of 7%, chosen on the basis that this
provided the greatest distinction between low and high
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figures. That this figure was selected from the data and then
applied back to it, and not validated upon a separate data set
weakens the findings in this study. The same criticism can be
levelled at Clark et al. (1989), who found ploidy alone to be
of independent prognostic significance in a group of 345
patients with node-negative breast cancer, DNA diploid
tumours showing an 11% survival advantage at 7 years in
univariate analysis which remained significant upon mul-
tivariate analysis. They found SPF to be of no additional
value in DNA aneuploid patients, but that it was a univariate
predictor of survival in DNA diploid patients at cutoffs
between high and low SPF of 5.0-9.0%, with a survival
advantage to those falling below the cutoff. This effect
remained in multivariate analysis using the figure of 6.7%,
again not validated upon data from which it was not derived,
and furthermore a figure which put 87% of cases into the
low SPF group.
Hedley et al. (1987), the originators of the technique for
utilising paraffin-embedded material for flow cytometry, per-
formed flow cytometry upon 490 node-positive tumours, with
6 or more years of follow-up. In their series, patients with
DNA diploid tumours showed improved survival in
univariate analysis, but this effect was no longer evident in
multivariate analysis. Tumours with a low SPF showed a
survival advantage, using a cutoff very near the median, but
this was not evident in multivariate analysis, predominantly
due to a strong association with tumour grade.
Kallioniemi et al. (1988) followed 308 patients for 8 years,
and found a large univariate survival disadvantage for
aneuploid tumours (relative risk 3.0), which was not, how-
ever, borne out in multivariate analysis. Ploidy and SPF
could be combined to create three prognostic groups which
were independent predictors of survival, although once again
this relied upon cutoffs determined by examination of the
data. Finally, Fisher et al. (1991) have reported upon results
from the NSABP-04 trial in 398 patients. This represented
only 54% of available tumour blocks, the remainder failing
to provide adequate histograms. In this series, ploidy did not
predict 10 year survival in univariate analysis. SPF was
divided at the median appropriate to that tumour's ploidy,
with low SPF tumours having a survival advantage at 10
years of 14%. This result has remained significant in mul-
tivariate analysis, although they noted that low SPF tumours
still had only a 53% survival at this length of follow-up.
Of the above reports, only two of seven find ploidy alone
to be an independent predictor of survival, whilst five of six
find SPF or a combination of ploidy and SPF to be such.
Our own results are in line with these conclusions, with a
non-significant survival difference of only 3% in favour of
DNA diploid tumours at 10 years of follow-up despite hav-
ing over 100 patients still at risk, with a relative hazard of
1.20 to aneuploid tumours. The relative risk observed in
multivariate analysis is almost exactly the same, unimproved
by the allowance for effects from other variables. In respect
of SPF, our results are compatible with the trend toward
improved survival in the low SPF tumours, with an observed
survival advantage to this group of 5% at 10 years in DNA
diploid tumours, and of 11% at that stage in DNA aneup-
loid tumours. That these results are not statistically
significant may represent a type II statistical error. The
extent of this potential error can be assessed from the broad
confidence intervals for the relative hazards calculated for
ploidy and SPF. The relatively low observed level of risk in
high SPF tumours may also reflect our decision to divide
SPF at the median rather than at a level chosen from the
data, a process which however is open to criticism as stated
already.
The assignment of DNA index and SPF are subject to a
number of technical pitfalls. We know from cytogenetic
studies that all tumours contain abnormal quantities of
DNA. The DNA index at which a tumour becomes interp-
retable as DNA aneuploid is arbitrary, depending upon the
quality of the flow cytometry. Tumours with grossly abnor-
mal DNA content may also be difficult to define as DNA
aneuploid, in situations where the number of DNA aneuploid
cells is low, in which case the DNA aneuploid peak may be
obscured by background counts, or by the DNA diploid
G2/M peak. It is also presumed that tumours are consistent
in their ploidy, that is that there is no variation in DNA
content between different areas of tumour. However, there is
good evidence of spacial heterogeneity of ploidy within the
literature (Fuhr et al., 1991; Kallioniemi, 1988). The calcula-
tion of SPF by the use of computer models presents further
problems. Firstly, SPF is not interpretable in all tumours.
Computer models of DNA histograms assume that all peaks
are Gaussian, which is observably not always so. It is also
necessary to substract background counts from the histogram
which introduces an element of subjectivity into the process
of SPF estimation.
In conclusion, we have demonstrated no statistically
significant independent effect upon long-term survival in
breast cancer for either tumour ploidy or S-phase fraction.
The technical factors which limit the accuracy and rep-
roducibility of this information may at least partly explain
these findings, which upon critical analysis are borne out by
previous studies. The potential of flow cytometric indices of
DNA as prognostic factors in breast cancer is limited in our
hands.
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